Lung cancer is the leading cause of cancer-related death worldwide.[@b1] To improve the clinical outcomes of lung cancer, new therapeutic agents have been developed including epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs). EGFR-TKIs display significant efficacy against *EGFR*-mutated non-small cell lung cancers (NSCLCs) by inhibiting EGFR-AKT signaling.[@b2]--[@b4] However, most of these malignancies eventually acquire resistance to EGFR-TKIs.[@b5],[@b6] Several mechanisms of acquired resistance to EGFR-TKIs have been elucidated, such as secondary *EGFR* T790M[@b5] and minor mutations,[@b6] *MET* amplification,[@b7] activation of the MET/hepatocyte growth factor axis,[@b8] AXL upregulation,[@b9] and the acquisition of epithelial-to-mesenchymal transition (EMT) features.[@b10],[@b11] In addition, our group previously reported that stem cell-like properties were present in EGFR-TKI-resistant cells.[@b12]

Afatinib is an irreversible TKI for EGFR and HER2 that was approved by the United States Food and Drug Administration in 2013[@b13]; it exhibited *in vitro* and *in vivo* activity against the T790M variant[@b14] and suppressed the progression of NSCLC harboring the T790M mutation in clinical use.[@b15] In a randomized phase III trial, afatinib improved PFS compared with placebo in patients with NSCLC who experienced disease progression after reversible EGFR-TKI treatment.[@b16] However, acquired resistance to afatinib was also observed in most of the patients.[@b13],[@b16] Therefore, it remains a critical issue to elucidate and overcome the mechanisms of acquired resistance to irreversible EGFR-TKIs.

In this study, we established various NSCLC cell lines with acquired resistance to afatinib and investigated the molecular profile of resistant cells to uncover the mechanisms of resistance to irreversible EGFR-TKIs.

Materials and Methods
=====================

Cell lines and reagents
-----------------------

*EGFR*-mutant HCC827 (exon 19 del. E746-A750), PC-9 (exon 19 del. E746-A750), HCC4006 (exon 19 del. L747-A750, P ins), and HCC4011 (L858R) cells were used in this study. These cell lines excluding PC-9 were kindly provided by Dr Adi F. Gazdar (The University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA), who established these lines with Dr John D. Minna.[@b17],[@b18] PC-9 cells were obtained from Immuno-Biological Laboratories (Takasaki, Gunma, Japan). All cell lines were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum and grown in a humidified incubator with 5% CO~2~ at 37°C. Acquired afatinib-resistant sublines were established using the following procedures: (i) cells were exposed to afatinib with stepwise escalation from 10 nM to 2 μM over 6 months; (ii) cells were intermittently and briefly exposed to the drug at 2 μM for 6 months, (iii) cells were subjected to the drug with stepwise escalation from 1 nM to 2 μM for 3 months; and (iv) cells were continuously exposed to the drug at 2 μM for up to 3 months. The afatinib-resistant sublines established using method \#1 were designated as the name of the parental cell lines followed by "-AR1," e.g., HCC827-AR1. Similarly, the sublines established using methods \#2, \#3, and \#4 were designated as the name of parental cell lines followed by "-AR2," "-AR3," and "-AR4," respectively (Table[1](#tbl1){ref-type="table"}). Of note, acquired resistance to drugs was defined as exhibiting a higher IC~50~ value than the parental cell line.

###### 

Afatinib-resistant cell lines and resistant mechanisms

  Cell lines    Method of drug exposure                    *EGFR* T790M mutation   *MET* amplification   EMT   Stem cell markers
  ------------- ------------------------------------------ ----------------------- --------------------- ----- -------------------
  HCC827        N/A                                        --                      --                    --    --
  HCC827-AR1    Stepwise, 10 nM                            --                      --                    \+    \+
  HCC827-AR2    Intermittent (briefly), 2 μM               --                      \+                    --    --
  HCC827-ACR    Continuous, Crizotinib 0.2 μM              --                      \+                    \+    \+
  HCC827-AR3    Stepwise, 1 nM                             --                      \+                    --    --
  HCC827-AR4    Intermittent (as long as possible), 2 μM   --                      --                    \+    \+
  PC-9          N/A                                        --                      --                    --    --
  PC-9-AR1      Stepwise, 10 nM                            --                      --                    --    --
  PC-9-AR2      Intermittent (briefly), 2 μM               --                      --                    --    --
  HCC4006       N/A                                        --                      --                    --    --
  HCC4006-AR1   Stepwise, 10 nM                            --                      --                    \+    \+
  HCC4006-AR2   Intermittent (briefly), 2 μM               --                      --                    \+    --
  HCC4011       N/A                                        --                      --                    --    --
  HCC4011-AR1   Stepwise, 10 nM                            --                      \+                    --    --
  HCC4011-AR2   Intermittent (briefly), 2 μM               --                      --                    --    --

EGFR, epidermal growth factor receptor; EMT, epithelial to mesenchymal transition; N/A, not applicable.

Afatinib and crizotinib were purchased from Synkinase Pty ltd. (San Diego, CA, USA) and Sigma-Aldrich (St. Louis, MO, USA), respectively. Docetaxel was purchased from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). Bortezomib was purchased from LC Laboratories (Woburn, MA, USA).

The primary antibodies used for western blot analysis were as follows: anti-EGFR, phospho-EGFR (Tyr1068), HER-2, phospho-HER2 (Tyr877), Akt, phospho-Akt (Ser473), p44/p42 mitogen-activated protein kinase (MAPK), phospho-p44/p42 MAPK, Met, phospho-Met (Tyr1234/1235), TCF8/ZEB1, E-cadherin, vimentin (Cell Signaling Technology, Danvers, MA, USA), and β-actin (Merck Millipore, Billerica, MA, USA). The following secondary antibodies were used: goat anti-rabbit or anti-mouse immunoglobulin G-conjugated horseradish peroxidase (Santa Cruz Biotechnology, Dallas, TX, USA).

Western blot analysis
---------------------

Cells were harvested at 80--90% confluence, and cellular proteins were extracted with lysis buffer \[RIPA buffer, phosphatase inhibitor cocktail 2 and 3 (Sigma-Aldrich), and Complete Mini (Roche, Basel, Switzerland)\]. Total proteins were separated with electrophoresis and electroblotted using the Trans-Blot Turbo Transfer system (Mini-PROTEAN TGX Precast Gel and Trans-Blot Turbo Mini PVDF Transfer Pack) (Bio-Rad, Hercules, CA, USA). After blocking with 5% non-fat dry milk and 0.1% Tween 20 in Tris-buffered saline, the membranes were incubated at 4°C overnight with primary antibodies. The membranes then were developed with secondary antibodies. Monoclonal anti-actin antibody was used as an equal loading control. To detect specific signals, the membranes were examined using ECL Prime Western Blotting Detection System (GE Healthcare, Amersham, UK) and LAS-3000 (Fujifilm, Tokyo, Japan).

Fluorescence immunocytochemistry
--------------------------------

Cells were cultured and fixed by 4% formaldehyde on chamber slide, and blocked in 5% normal goat serum (Sigma-Aldrich) in PBS containing 0.3% Triton X-100 (Sigma-Aldrich) for 1 h at room temperature. The blocking solution was aspirated and sections were incubated overnight at 4°C in primary antibodies diluted in PBS with 0.3% Triton and 1% bovine serum albumin (BSA) (Sigma-Aldrich). Primary and secondary antibody were used PathScan EMT Duplex IF Kit (Cell Signaling Technology), and chromatin was counterstained using ProLong Gold antifade reagent with DAPI (Thermo Fisher Scientific, Waltham, MA, USA).

DNA and RNA extraction
----------------------

Genomic DNAs were extracted from cell lines using a DNeasy Blood and Tissue Kit (Qiagen, Venlo, the Netherlands). Total RNAs were extracted from cell lines using an RNeasy Mini Kit (Qiagen). The complementary DNA (cDNA) was synthesized from total RNA using High-Capacity cDNA Reverse Transcription Kits (Thermo Fisher Scientific), according to the manufacturer's instructions.

DNA analyses
------------

*EGFR* exon 20 mutation was examined using direct sequencing as previously reported.[@b19] The primer sequences are shown in Supplementary [Table S1A](#sd4){ref-type="supplementary-material"}. Copy number gains (CNGs) of *EGFR* and *MET* were determined by a quantitative real-time PCR assay using Power SYBR Green PCR Master Mix (Thermo Fisher Scientific) as previously reported.[@b20] *LINE-1* gene was used as a reference gene. The relative copy number of each sample was determined by comparing the ratio of the target gene to *LINE-1* in each sample with the ratio of these genes in human genomic DNA (Merck Millipore). The primer sequences are shown in Supplementary [Table S1B](#sd4){ref-type="supplementary-material"}.

mRNA and microRNA expression analysis by quantitative reverse transcription-PCR
-------------------------------------------------------------------------------

The gene expression of the putative stem cell markers *ALDH1A1* and *ABCB1* were analyzed by quantitative reverse transcription-PCR using cDNAs, TaqMan Gene Expression Assays, and the ABI StepOnePlus Real-Time PCR Instrument (Thermo Fisher Scientific). mRNA and microRNA (miR) expression was calculated using delta-delta-CT method. The glyceraldehyde-3-phosphate dehydrogenase (*GAPDH*) gene and miR-374 were used as the endogenous control for mRNA and miR expression analyses, respectively. The catalog numbers of TaqMan assays are shown in Supplementary [Tables S1C,D](#sd4){ref-type="supplementary-material"}.

Cell proliferation assay
------------------------

Cell proliferative ability was determined by a modified MTS assay using CellTiter 96 AQueous One Solution Reagent (Promega, Fitchburg, WI, USA) as previously reported.[@b21] The antiproliferative effects are shown as the 50% inhibitory concentration (IC~50~).

DNA methylation analysis
------------------------

The DNAs were subjected to bisulfite treatment using an Epitect Bisulfite Kit (Qiagen). The DNA methylation statuses were analyzed using these bisulfite DNAs and methylation-specific PCR as previously reported.[@b21],[@b22] The primer sequences are shown in Supplementary [Table S1E](#sd4){ref-type="supplementary-material"}.

Cell growth assay
-----------------

Cells were plated in 96-well plate at a density of 2.0 × 10^3^ cells per well and cultured for 120 h at drug-free condition. Four images per well were taken every 6 h using IncuCyteZOOM. (Essen BioScience, Ann Arbor, MI, USA), and cell confluence was evaluated using IncuCyte ZOOM 2015A software (Essen BioScience) as previously reported.[@b23]

Soft agar colony formation assay
--------------------------------

Cells were plated in 24-well plate with Ultra-Low Attachment surface (Corning Inc., Corning, NY, USA) at a density of 2.5 × 10^3^ cells per well and cultured for 21 days in RPMI1640 with 10% FBS and 0.3% agarose. RPMI1640 with 10% FBS were added to the top of agar layer and exchanged every 3 days. Nine images per well were taken every day using IncuCyteZOOM. The colony formation was defined as the cell aggregates occupying an area at least 8000 μm^2^ (about 100 μm diameter) and the occupied area were measured using IncuCyte ZOOM 2015A software.[@b24]

Antibody array
--------------

Cells were cultured with or without 2 μM afatinib for 6 h. After that, they were harvested at 80--90% confluence and cellular proteins were extracted. Antibody array for these proteins were performed using PathScan RTK Signaling Antibody Array Kit (Cell Signaling Technology) as manufacturer's recommendation.

Next generation sequencing
--------------------------

The targeted mRNAseq for 100 stem cell-related markers was performed. The libraries were prepared using TruSeq Targeted RNA Expression Kit (Illumina, San Diego, CA, USA) and sequencing were performed using MiSeq Reagent Kit v2 (Illumina) and MiSeq Desktop Sequencer (Illumina) as manufacturer's recommendation. Data analysis was performed using Illumina MiSeq Reporter version 2.5.1 (Illumina).

Xenograft model and immunohistochemical staining
------------------------------------------------

All experimental animals were housed under specific pathogen-free conditions and handled in accordance with the Policy on the Care and Use of Laboratory Animals, Okayama University. HCC827 and HCC827-AR1 cells were inoculated into 5--8-week-old female non-obese diabetic/severe combined immunodeficient (NOD/SCID) mice that were purchased from Charles River Laboratories Japan (Yokohama, Japan). Each suspension of cell lines was subcutaneously injected at 1 × 10^6^ cells in 300 μL of serum-free RPMI 1640 medium with Matrigel Basement Membrane Matrix (Corning). After tumor formation, mice were sacrificed, and tumors were harvested. The formalin-fixed and paraffin-embedded tissues of these tumors were stained immunohistochemically using anti-ALDH1 antibody (Becton Dickinson, Franklin Lakes, NJ, USA) as previously reported.[@b25]

Statistical analyses
--------------------

Statistical analysis was performed using GraphPad Prism, version 6.0.3, J (GraphPad Software, San Diego, CA, USA) and R statistical software version 3.2.0[@b26] with Bioconductor packages 'Heatplus'.[@b27],[@b28] Values of *P* \< 0.05 were considered as statistically significant.

Results
=======

*EGFR*-mutated cell lines that acquired resistance to afatinib
--------------------------------------------------------------

We established 10 afatinib-resistant cell lines from four parental NSCLC cell lines harboring activating *EGFR* mutations. Initially, we tried to establish afatinib-resistant cell lines via continuous exposure to a high concentration of afatinib (2 μM), but this was unsuccessful. Therefore, we used two exposing procedures, namely intermittent high-dose exposure and stepwise dose escalation from 10 nM, which is higher than the IC~50~ of the parental cell lines and similar to the *in vitro* IC~50~ for EGFR with L858R/T790M mutations.[@b14] The characteristics of these cell lines including the IC~50~ values of afatinib are shown in Table[1](#tbl1){ref-type="table"}. The representative examples of the expression of EGFR, HER2, and their downstream targets are shown in Supplementary [Figure S1](#sd1){ref-type="supplementary-material"}.

*EGFR* T790M mutation and *MET* amplification in afatinib-resistant cell lines
------------------------------------------------------------------------------

The T790M mutation was not detected in all 10 afatinib-resistant sublines by direct sequencing. The CNGs of *MET* were detected in HCC827-AR2 and HCC827-AR3 significantly and in HCC4011-AR1 slightly ([Fig. 1](#fig01){ref-type="fig"}).

![Copy number gains of *MET* and *EGFR* in *EGFR*-mutant lung cancer cell lines and their afatinib-resistant sublines. (a) The copy numbers of *MET* examined by real-time PCR were significantly amplified in HCC827-AR2, -AR3 and -ACR cells and slightly amplified in HCC4011-AR1 cells. (b) The copy number of *EGFR* in HCC827-ACR cells was approximately half of that in the parental cell line. All experiments were performed at least three times, and error bars indicate standard deviations.](cas0106-1377-f1){#fig01}

Acquired resistance to afatinib plus crizotinib in *MET*-amplified cell line
----------------------------------------------------------------------------

HCC827-AR2 with *MET* amplification was sensitive to combination treatment with afatinib and crizotinib, which is a MET inhibitor (Table[2](#tbl2){ref-type="table"}). We had an interest in whether this combined treatment completely overcomes resistance to afatinib in HCC827-AR2 cells. Therefore, HCC827-AR2 cells were treated with 2 μM afatinib and 0.2 μM crizotinib via continuous exposure. Finally, a subline resistant to afatinib plus crizotinib treatment was established from HCC827-AR2 cells within 2 months of drug exposure and was named HCC827-ACR. The CNG of *MET* was retained in HCC827-ACR cells, although copy number of *EGFR* was reduced to approximately half of that in the parental cell line ([Fig. 1](#fig01){ref-type="fig"}).

###### 

IC~50~ values (μM) against various agents in *EGFR*-mutant NSCLC cell lines

  Cell Lines    EGFR-TKI                               Chemotherapeutic agent                  MET inhibitor   Protease inhibitor                    
  ------------- -------------------------------------- --------------------------------------- --------------- ------------------------------------- --------
  HCC827        0.0019                                 0.0031                                  6.9             0.0018                                0.0082
  HCC827-AR1    \>10[†](#tf2-1){ref-type="table-fn"}   \>1[†](#tf2-2){ref-type="table-fn"}     7.9             4.8[†](#tf2-1){ref-type="table-fn"}   0.0094
  HCC827-AR2    4.1[†](#tf2-2){ref-type="table-fn"}    0.0042                                  4.6             0.00019                               0.0018
  HCC827-ACR    \>10[†](#tf2-2){ref-type="table-fn"}   \>1[†](#tf2-2){ref-type="table-fn"}     N/A             6.3[†](#tf2-2){ref-type="table-fn"}   0.0084
  HCC827-AR3    4.3[†](#tf2-2){ref-type="table-fn"}    0.0022                                  N/A             N/A                                   0.0068
  HCC827-AR4    4.8[†](#tf2-2){ref-type="table-fn"}    0.003                                   N/A             N/A                                   0.0066
  PC-9          0.0023                                 0.0022                                  N/A             N/A                                   0.014
  PC-9-AR1      2[†](#tf2-2){ref-type="table-fn"}      0.0023                                  N/A             N/A                                   0.041
  PC-9-AR2      2.2[†](#tf2-2){ref-type="table-fn"}    0.0056                                  N/A             N/A                                   0.0093
  HCC4006       0.0031                                 0.0062                                  N/A             N/A                                   0.019
  HCC4006-AR1   3.7[†](#tf2-2){ref-type="table-fn"}    0.062[†](#tf2-2){ref-type="table-fn"}   N/A             N/A                                   0.036
  HCC4006-AR2   5.4[†](#tf2-2){ref-type="table-fn"}    0.0011                                  N/A             N/A                                   0.038
  HCC4011       0.0052                                 0.0012                                  1.4             0.0041                                0.001
  HCC4011-AR1   3.3[†](#tf2-2){ref-type="table-fn"}    0.0018                                  1.5             7.1[†](#tf2-2){ref-type="table-fn"}   0.0042
  HCC4011-AR2   4.1[†](#tf2-2){ref-type="table-fn"}    0.0019                                  1.8             4.4[†](#tf2-2){ref-type="table-fn"}   0.0049

DOC, docetaxel; EGFR-TKI, epidermal growth factor receptor-tyrosine kinase inhibitor; N/A, not applicable.

The ratio of the IC~50~ value in each resistant line to that in the parental line is higher than five-fold.

Acquisition of EMT or other features in afatinib-resistant cell lines
---------------------------------------------------------------------

HCC827-AR1, HCC827-ACR, HCC827-AR4, and all HCC4006 sublines exhibited downregulation of E-cadherin, which is the epithelial marker, and upregulation of vimentin, which is the mesenchymal marker ([Fig. 2a,b](#fig02){ref-type="fig"}). ZEB-1, one of the regulators of EMT and a target of the miR-200c, was also expressed in cells with acquired resistance and EMT features. In fact, the expression of miR-200c was downregulated, and the methylation of the promoter regions in miR-200c was observed in these cell lines (Suppl. Fig. S2). Of note, although HCC827-AR2 that was a *MET*-amplified cell line did not display EMT features, HCC827-ACR, which was derived from HCC827-AR2 by afatinib plus crizotinib exposure, acquired EMT features. For PC-9 and it resistant sublines, antibody array was performed because the mechanisms of resistance to afatinib in PC-9 sublines were not identified with other assays mentioned above. In the result, phospho-stat1 upregulation by afatinib exposure was shown in PC-9 sublines although not shown in parental cell line,

![Epithelial to mesenchymal transition in afatinib-resistant cell lines. (a) HCC827-AR1, -ACR, -AR4, HCC4006-AR1, and -AR2 displayed downregulation of E-cadherin and upregulation of vimentin. (b) Immunofluorescence cytochemistry of E-cadherin and vimentin on HCC827 and its several sublines are shown. HCC827 displayed epithelial phenotype although HCC827-AR1 and ACR displayed mesenchymal phenotype. Scale bars, 10 μm.](cas0106-1377-f2){#fig02}

Acquisition of stem cell-like properties in afatinib-resistant cell lines
-------------------------------------------------------------------------

*ALDH1A1* and *ABCB1*, which are putative stem cell markers, were overexpressed in HCC827-AR1, HCC827-ACR, and HCC4006-AR1 cells ([Fig. 3a](#fig03){ref-type="fig"}). These cell lines also exhibited EMT features. HCC827-AR1 and HCC827-ACR were displayed higher colony formation ability than HCC827 in soft agar assay ([Fig. 3b](#fig03){ref-type="fig"}). The mouse xenograft model of HCC827-AR1 cells displayed significant *ALDH1* expression, although the parental HCC827 cell line did not exhibit *ALDH1* expression by immunohistochemical staining ([Fig. 3c](#fig03){ref-type="fig"}). The fold changes of expressions of stem cell-related markers in HCC827 sublines from its parental cell line, which were explored using next generation sequencing, were shown in [Figure 4](#fig04){ref-type="fig"}. Among the 100 stem cell-related markers examined, the expressions of *fibroblast growth factor receptor 1 (FGFR1)*, *membrane metallo-endopeptidase (MME), Notch1* and *CD44* in HCC827-AR1, HCC827-ACR, and HCC827-AR4 were significantly increased from parental cell lines (*P* \< 0.05), but not increased in *MET*-amplified sublines. Additionally, HCC827-AR1 and -ACR displayed higher cell growth ability than their respective parental cell lines (Suppl. Fig. S3). These findings above supported that the established cell lines had stem cell-like properties.

![Stem cell-like properties of afatinib-resistant cell lines. (a) The putative stem cell markers, *ALDHA1* and *ABCB1* were overexpressed in HCC827-AR1, HCC827-ACR, and HCC4006-AR1 cells. The error bars indicate standard deviations. (b) The images of colonies of HCC827, -AR1 and --ACR were represented and time-lapse change of occupied area of the colonies in soft agar colony formation assays were shown. Scale bars, 100 μm. (c) In immunohistochemical staining of mouse xenograft models, HCC827 cells were negative for ALDH1 expression, but HCC827-AR1 cells displayed ALDH1 expression. Scale bars, 100 μm.](cas0106-1377-f3){#fig03}

![The changes of expressions of stem cell-related markers in HCC827 sublines. The result of target mRNAseq for 100 stem cell-related markers in in HCC827 sublines was shown. The fold changes of gene expressions from parental cell line (HCC827) were displayed as heatmap.](cas0106-1377-f4){#fig04}

Afatinib-resistant cell lines with stem cell-like properties displayed the resistance to chemotherapeutic agents
----------------------------------------------------------------------------------------------------------------

HCC827-AR1, HCC827-ACR, and HCC4006-AR1 cells harboring EMT feature and expressing stem cell markers acquired resistance to both afatinib and docetaxel. Additionally, all cell lines were sensitive to bortezomib, which is a proteasome inhibitor. The IC~50~ values of these drugs in all cell lines are shown in Table[2](#tbl2){ref-type="table"}.

Discussion
==========

In this study, we established nine cell lines that acquired resistance to afatinib and one cell line that acquired resistance to afatinib plus crizotinib, and examined these resistant mechanisms. In the result, T790M mutation was not detected in all 10 cell lines, although acquisition of *MET* amplification, EMT, and stem cell-like properties were observed. The mechanisms of resistance to afatinib in PC-9 sublines were still unclear, although upregulation of phospho-stat1 by afatinib exposure were shown in PC-9 sublines. Further study is necessary.

Afatinib was effective against the NSCLC cell line harboring *EGFR* L858R/T790M mutations, and a transgenic mouse model of *de novo EGFR* L858R/T790M-driven lung cancer.[@b14] In the clinical environment, there are some patients with NSCLC harboring *EGFR* exon 19 deletion and T790M mutation, who were sensitive to afatinib.[@b29] However, Kim *et al*.[@b30] reported acquired resistance to afatinib associated with T790M mutation. Although the reason for this discrepancy is uncertain, it may be caused by the initial concentration of afatinib, as our results along with previous reports suggest that the drug concentration affects the establishment of the mechanism of drug resistance. We previously reported that gefitinib-resistant cell lines established via step-wise exposure to the drug acquired *EGFR* T790M mutation or *MET* amplification, although those established via high-dose exposure to the drug did not acquire the T790M mutation.[@b21] In this study, T790M mutation was not detected in our resistant sublines, and the initial concentrations of afatinib were higher than the IC~50~ for cells featuring *EGFR* L858R/T790M mutation[@b14] in nine of the 10 cell lines. On the contrary, Kim *et al*.[@b30] started afatinib exposure using a dose of \< 10 nM. These facts suggest that the first-line use of afatinib with sufficient dosage may tend to avoid acquired resistance associated with T790M mutation. Regarding the *MET* amplification observed in the sublines derived from HCC827 and HCC4011 in the current study, it had also been identified in the resistant sublines from same parental cell lines established with gefitinib exposure in the previous reports.[@b7],[@b21] This fact suggests that some cell lines may have preferred resistant mechanism to EGFR-TKIs.

It is uncertain whether preventing T790M mutation contributes to prolonging the overall survival of patients. NSCLC harboring activating *EGFR* mutation and T790M mutation exhibit indolent progression compared with NSCLC harboring only activating *EGFR* mutations,[@b31] and the prognosis of patients with T790M after EGFR-TKI failure was better than that of patients lacking this mutation.[@b32] In addition, T790M-mutant EGFR-selective EGFR-TKIs were recently developed.[@b33],[@b34] In the current and our previous studies,[@b12] the strict selection of cancer cells with a sufficient concentration of EGFR-TKIs may prevent the acquisition of conventional resistance mechanisms, such as T790M or *MET* amplification, and may cause cancer cells to acquire stem cell-like properties. As these cell lines displayed higher growth rate than their respective parental cell lines (Suppl. Fig. S3) and resistance to both EGFR-TKIs and chemotherapeutic agents, the acquisition of stem cell-like properties may have an unfavorable influence on overall survival.

The HCC827-ACR cell line, the afatinib and crizotinib-resistant cell line, acquired resistance associated with stem cell-like properties, although HCC827-AR2 cells, the parental cell line of HCC827-ACR cells, harbored *MET* amplification but did not display EMT or stem cell-like properties. Suda *et al*.[@b35] also observed the acquisition of EMT features beyond T790M mutation and *MET* amplification. Previous studies attempted to overcome the conventional mechanisms of resistance to EGFR-TKIs, such as a change of conformation of EGFR[@b5],[@b6] or the dependence on another receptor tyrosine kinase (RTK),[@b7],[@b8],[@b36] by targeting RTKs.[@b33],[@b34],[@b37],[@b38] However, our findings suggest that this approach may result in resistance associated with stem cell-like properties. Therefore, strategies targeting other hallmarks of cancer[@b39] may be required to overcome these mechanisms of resistance. In the current study along with our previous study,[@b12] a proteasome inhibitor, bortezomib displayed antitumor effect in EGFR-TKI-resistant cell lines with stem cell-like properties in our study.

In conclusion, we established cell lines with acquired resistance to afatinib and one cell line that acquired resistance to the combination of afatinib plus crizotinib. As several cell lines displayed stem cell-like properties, overcoming resistance to EGFR-TKIs associated with stem cell-like properties may be a critical component of the treatment of NSCLCs.
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